Search results
19 sty 2023 · Monitoring. Digoxin has a narrow therapeutic index. The recommended serum levels stand between 0.8 to 2 ng/mL. When measuring a digoxin serum level, drawing blood at least 6 to 8 hours after the last dose is essential. The toxicity increases as the serum drug levels increase above 2.0 ng/mL.
3 sty 2023 · It is recommended to reduce the dose of digoxin by 30–50% and closely monitor serum digoxin levels to determine effects; Macrolides (e.g. azithromycin, clarithromycin and erythromycin) have been reported to increase serum digoxin levels.
21 sie 2023 · The initiation of digoxin therapy has been divided into rapid and slow digitalization followed by the maintenance digoxin dose, and the proposed regimens vary considerably. The following principles should be viewed as a general guide to the use of digoxin for its inotropic or electrophysiologic effects, which must be modified according to ...
30 maj 2006 · Monitoring Serum Digoxin Concentration Serum digoxin concentrations should be monitored to guide therapy in patients at high risk for developing digoxin intoxication ( Table 4 ). An SDC should be obtained ≈14 to 21 days after therapy initiation.
11 wrz 2024 · When assessing a patient for digoxin toxicity, our findings support consideration of the patient's age, renal function, nature of exposure (acute, acute-on-chronic, chronic), serum digoxin level, most-recent time of digoxin ingestion, potential drug-drug interactions with digoxin, heart rate, blood pressure, gastrointestinal fluid loss or ...
27 gru 2023 · The therapeutic range for serum digoxin concentration is between 0.7 nanograms/mL and 2.0 nanograms/mL. The concentration can thus determine the likelihood of toxicity; in particular: Levels less than 1.5 nanograms/mL in the absence of hypokalaemia indicate that digoxin toxicity is unlikely.
16 sie 2022 · Slow digoxin loading — Slow oral digitalization, generally preferred for most patients, can be achieved by starting a maintenance dose of 0.125 to 0.25 mg daily. A steady state will be achieved after five cycles of the drug half-life (T1/2ß), which is approximately 7 to 10 days in the average subject.
